Domain description | Sequence range/Domain coverage | Original E-values [HMMER2/HMMER3] | [coverage/FPR]ratio[coverage/FPR]fc E-value | Total FPR | RMSD/%Id/Structural alignment range (1GPJ|A:pdb) | Function description of representative pdb |
---|---|---|---|---|---|---|
PF01488.15 | 156–292/ | 1.90e–67/ | 0.995/0.00 | 0.00 | 3.12/ | Synthesis of aromatic amino-acids in shikimate pathway [39]; NADP+ driven |
Shikimate_DH | 1 | 3.21e–40 | 0.995/0.00 | 14.0/ | ||
length:170 | 149–304: | |||||
pdb:1NVT|A | 110–270 | |||||
PF03807.12 | 169–268/ | 8.73e–06/ | 0.975/0.00 | 0.00 | 3.75/ | Conversion of insoluble ferrin (Fe3+) to soluble ferrin(Fe2+) [40]; NADP+ driven |
F420_oxidored | 1 | 2.93e–07 | 0.980/0.00 | 14.0/ | ||
length:123 | 168–281: | |||||
pdb:2VNS|A | 29–150 | |||||
PF02882.14 | 131–258/ | 5.34e–01/ | 0.780/0.00 | 0.00 | 3.29/ | Interconversion of 1-carbon derivatives of tetrahydrofolate; substrates for methione, thymidylate and purine syntheses [41]; NADP+ driven |
THF_DHG_CYH_C | 1 | 8.87e–03 | 0.795/0.00 | 10.7/ | ||
length:205 | 149–307: | |||||
pdb:1A4I|A | 147–296 | |||||
PF03446.10 | 167–321/1 | 3.00e–01/ | 0.700/0.00 | 0.00 | 3.57/ | Decarboxylating reduction of 6-phosphogluconate to ribose 5-phosphate [42]; NADP+ driven |
NAD_binding_2 | 1.27e–03 | 0.710/0.00 | 11.4/ | |||
length:235 | 167–288: | |||||
pdb:1PGQ|A | 2–129 | |||||
PF02826.14 | 127–269/ | 8.79e–03/ | 0.645/0.00 | 0.00 | 3.05/ | Purine biosynthesis [43]; NADP+ driven |
2-Hacid_dh_C | 1 | 5.29e–09 | 0.670/0.00 | 11.8/ | ||
length:260 | 161–264: | |||||
pdb:3ORQ|A | 3–101 | |||||
PF00106.20 | 168–305/ | 1.10e–02/ | 0.640/0.00 | 0.00 | 3.00/ | Synthesis of tripinone from pseudotropine [44]; NADP+ driven |
adh_short | 1 | 5.53e–05 | 0.645/0.00 | 9.2/ | ||
length:225 | 164–265: | |||||
pdb:1IPE|A | 6–145 | |||||
PF08659.5 | 169–281/1 | 4.86e + 00/ | 0.57/0.01 | 0.01 | 3.62/ | Mammalian fatty acid synthase; a large multienzyme that catalyzes all steps of fatty acid synthesis [45]; NADP+ driven |
KR | 6.51e–03 | 0.725/0.00 | 9.0/ | |||
length:257 | 150–291: | |||||
pdb:2VZ9|A | 1651–1802 | |||||
PF13241.1 | 162–275/ | 9.13e–02/ | 0.535/0.01 | 0.02 | 4.17/ | Siroheme synthesis from uro’gen III in tetrapyrrole biosynthesis [46]; NADP+ driven |
NAD_binding_7 | 1 | 7.38e–03 | 0.535/0.01 | 12.0/ | ||
length:379 | 160–304: | |||||
pdb:1PJQ|A | 5–150 | |||||
PF13460.1 | 170–344/ | 2.40e–02/- | 0.495/0.03 | 0.06 | 3.26/ | Synthesis of bilverdin from bilirubin [47]; NADP+ driven |
NAD_binding_10 | 1 | 0.490/0.03 | 11.5/ | |||
Length:362 | 168–288: | |||||
pdb:1HDO|A | 4–152 | |||||
PF01408.17 | 168–265/1 | 8.97e–02/- | 0.445/0.11 | 0.20 | 3.73/ | Cleavage of non-reducing N-acetylgactosamine from blood group ABO antigens [48]; NAD+ driven |
GFO_IDH_MocA | 0.450/0.10 | 9.4/ | ||||
length:188 | 167–303: | |||||
pdb:2IXB|A | 20–164 | |||||
PF02254.13 | 170–285/ | 3.55e–02/- | 0.400/0.18 | 0.33 | 3.31/ | NAD-mediated conformation switch for K+ influx control [49]; NAD+ driven |
TrkA_N | 1 | 0.420/0.15 | 10.5/ | |||
length:195 | 168–300: | |||||
pdb:1LSS|A | 1–132 | |||||
PF03949.10 | 146–323/ | 3.44e–02/- | 0.140/0.66 | 0.70 | 3.22/ | Oxidation of malate to pyruvate [50]; NAD+ driven |
Malic_M | 1 | 0.485/0.04 | 6.4/ | |||
length:324 | 149–305: | |||||
pdb:1DO8|A | 298–494 | |||||
PF07991.7 | 165–233/ | -/1.65e–04 | 0.205/0.53 | 1.07 | 3.49/ | Synthesis of branched side of valine and isoleucine [51]; NADP+ driven |
IlvN | 0.42 | 0.205/0.54 | 9.7/ | |||
length:177 | 163–288: | |||||
pdb:1YVE|A | 121–252 |